Provectus Biopharmaceuticals (OTCQB: PVCT) Preclinical Study Shows Immune Benefits of PV-10 in Burn Healing
Key Developments Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) has reported new findings from independent preclinical research focused on its drug candidate PV-10. The study examined PV-10’s impact on immune response within a clinically relevant porcine model of burn wounds. PV-10, which consists of the company’s proprietary rose bengal sodium, was studied in collaboration with researchers at the University of Texas Medical Branch and Shriners Children’s Texas, with Provectus as the funding…
